Bioalmanac
AOD-9604
hGH fragment 176-191 · Anti-obesity drug 9604
A growth hormone fragment developed as an obesity drug. It completed human trials, and they did not show weight loss beyond placebo.
Storage
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C. Do not freeze once mixed.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
Reconstitution — 5 mg vial, 300 mcg dose
On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.
| Water added | Concentration | Volume to draw | Units | Doses per vial |
|---|---|---|---|---|
| 1 mL | 5 mg/mL | 0.06 mL | 6 units | 16.7 |
| 2 mL | 2.5 mg/mL | 0.12 mL | 12 units | 16.7 |
| 3 mL | 1.667 mg/mL | 0.18 mL | 18 units | 16.7 |
| 5 mL | 1 mg/mL | 0.3 mL | 30 units | 16.7 |
Dose ranges reported in sources
Descriptions of what sources report, not recommendations.
| Goal | Range | Frequency | Source |
|---|---|---|---|
| Trial dose | 1000–30000 mcg | Once daily across dose-ranging arms | Clinical trial |
| Commonly described dose | 300–500 mcg | Once daily | Community practice |
When to stop
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- Signs of infection at an injection site.
- Any new or unexplained symptom you would ordinarily see a doctor about.
Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.